Nicox has entered into a collaboration agreement with Novaliq to develop topical nitric oxide-donating phosphodiesterase-5 inhibitors and soluble guanylate cyclase stimulators, the company announced in a release.
The collaboration agreement will allow the companies to develop a novel topical ophthalmic formulation of Nicox’s NO-donating PDE5 inhibitors based on the water-free enabling EyeSol technology from Novaliq in order to lower IOP, according to the release.
“We have been impressed by Novaliq’s ability to successfully combine existing molecules and new chemical entities
Uncategorized